The nation of Zimbabwe has turned down a substantial US health deal valued at $367m (£272m) over five years because of Washington's request for sensitive information.
The decision was revealed after a government memo dated December was leaked, which showed Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
A government spokesperson later stated that the United States was demanding access to health data for scientific study and commercial purposes while was not willing to share the resulting advantages from future treatments.
"We will now turn to the difficult and regrettable task of ending our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had donated over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has urged more negotiations to reach a agreement suitable to all parties so the nation's critical HIV treatment initiative can proceed.
Wider Context
This rejection follows a comparable situation in neighbouring Kenya, where a court blocked a related health funding agreement after legal challenges were filed about the safety of Kenyans' medical information.
Since resuming office last year, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
The agency had managed aid for the American government, but Trump claimed its expenditure was "wasteful" and his administration was pursuing direct bilateral deals to boost transparency and accountability.
According to reports, Sixteen African countries have to date signed these new health pacts, representing more than $18.3bn in new funding.
Details of the Rejected Deal
This assistance for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this cooperation might have yielded extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently receiving HIV treatment via US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana maintained the proposed deal was "unfair".
"Our nation was requested to provide its genetic material and health information for a long time, without any corresponding guarantee of benefiting from any medical innovations – such as new medicines or tests – that could result from that shared data," he stated.
"Effectively, our nation would provide the raw materials for scientific discovery without any certainty that the end products would be available to our citizens if a new disease outbreak arise."
Sovereignty and Global Health
He also pointed out that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were upending systems already set up through the global health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework created to deal with future global health emergencies.
"This mechanism is intended to ensure that when a country provides its information, the benefits – including vaccines and treatments – are distributed fairly, not monopolised solely by those with the capability to create them."
The government's concerns over the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We welcome further dialogue with our US partners on how future collaboration might be arranged in a way that respects the independence and dignity of each country."
Health Experts Response
Medical experts expressed it acknowledged the official position, but urged that negotiations should continue given that much of the nation's Aids initiatives depended on international support.
"Where technical issues arise, including those relating to information security or agreement terms, these can often be addressed via technical clarification and negotiated safeguards," the group added.
This impasse emphasises the complex tensions between accepting much-needed international aid and safeguarding local interests in an increasingly data-driven world.